

**CAMSING HEALTHCARE LIMITED**  
(Incorporated in the Republic of Singapore)  
(Company Registration Number: 197903888Z)  
(the “Company”)

---

**RECEIPT OF APPROVAL IN-PRINCIPLE FROM THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED FOR THE LISTING AND QUOTATION OF THE SUBSCRIPTION SHARES AND THE CONVERSION SHARES**

---

*The Company would like to remind all shareholders that trading in the Company’s shares is currently suspended. Shareholders and investors are advised to exercise caution when dealing in the Company’s shares and to refrain from taking any action in respect of their shares and/or investment in the Company which may be prejudicial to their interest. Persons, who are in doubt, as to the action they should take, should consult their stockbroker, bank manager, solicitor, accountant or other professional advisers.*

*Capitalised terms in this announcement (this “Announcement”) shall have the same meanings as ascribed to them in the Company’s announcement dated 14 June 2023 and 6 February 2024 (the “Previous Announcements”), unless otherwise defined.*

**1. RECEIPT OF APPROVAL IN-PRINCIPLE**

1.1. The Board of Directors (the “Board” or “Directors”) of Camsing Healthcare Limited (the “Company”) refers to the Previous Announcements and is pleased to announce that the Company, has on 2 May 2024, obtained approval in-principle (the “AIP”) from the Singapore Exchange Securities Trading Limited (the “SGX-ST”) in respect of the listing of, and quotation for:

- (a) up to 60,000,007 Subscription Shares pursuant to the Placement, which includes:
  - (i) the placement of 26,000,007 Subscription Shares to Ms Duanmu Xiaoyi;
  - (ii) the placement of 22,000,000 Subscription Shares to Mr Chen Hao;
  - (iii) the placement of 4,000,000 Subscription Shares to Ms Liu Jing;
  - (iv) the placement of 4,000,000 Subscription Shares to Mr Ong Yaw Teh; and
  - (v) the placement of 4,000,000 Subscription Shares to Mr Steven Lim; and
- (b) up to 50,000,000 Conversion Shares upon conversion of the Bonds to be issued pursuant to the Issuance, which includes:
  - (i) the issuance of Bonds in the principal amount of S\$700,000 to Ms Duanmu Xiaoyi;
  - (ii) the issuance of Bonds in the principal amount of S\$900,000 to Mr Chen Hao; and
  - (iii) the issuance of Bonds in the principal amount of S\$900,000 to Ms Liu Jing,

on the Mainboard of the SGX-ST.

- 1.2. The AIP is subject to the following conditions:
- (a) compliance with the SGX-ST's continuing listing requirements;
  - (b) a written undertaking from the Company that it will comply with Listing Rules 740(30) and 1207(20) in relation to the use of the proceeds from the Proposed Placement and where proceeds are to be used for working capital purposes, the Company will disclose a breakdown with specific details on the use of proceeds for working capital in the Company's announcements on use of proceeds and in the annual report;
  - (c) a written confirmation from the Company that the Proposed Placement and Bonds do not contravene any laws and regulations governing the Company and the constitution of the Company;
  - (d) the Placees and the Bondholders maintaining their investment funds of S\$4.85m in escrow (which excludes the S\$250,000 advance from Ms Duanmu that has been paid out of the escrow account), until completion of the Proposed Placement and Proposed Issuance; and
  - (e) the Company sourcing and appointing one (1) additional Independent Director within three (3) months of the listing and quotation of the Subscription Shares and Conversion Shares. Such Independent Director shall be sourced via a third-party independent selection process and shall be subject to SGX-ST's approval.
- 1.3. The AIP is not to be taken as an indication of the merits of the New Investment, the Proposed Placement, the Proposed Issuance, the Subscription Shares, the Bonds, the Conversion Shares, the Company and/or its subsidiaries.
- 1.4. The Company will make further announcements relating to the New Investment as may be appropriate from time to time.
- 1.5. A circular to shareholders setting out, *inter alia*, the details of the New Investment, together with a notice convening the extraordinary general meeting to seek shareholders' approval for *inter alia*, the Subscription and the Issuance, will be made available on the SGX website at the URL <https://www.sgx.com/securities/company-announcements> in due course.

## **2. CAUTIONARY STATEMENT**

- 2.1. Shareholders should note that the New Investment remain subject to several conditions precedent and the approval of the Independent Shareholders at the meeting of the Shareholders to be convened to approve the Transaction Resolutions. There is no certainty or assurance that the conditions precedent can be fulfilled, or that the proposed transaction contemplated under the New Investment Agreements will be completed. Although the Company's shares are under suspension, shareholders and investors are advised to exercise caution when dealing in the Company's shares and to refrain from taking any action in respect of their shares and/or investment in the Company which may be prejudicial to their interest. Persons, who are in doubt, as to the action they should take, should consult their stockbroker, bank manager, solicitor, accountant or other professional advisers.

**BY ORDER OF THE BOARD**

Yeo Choon Tat  
Executive Director  
3 May 2024